

Water-soluble MnO nanocolloid for a molecular T1 MR imaging: A facile one-pot synthesis, in vivo T1 MR images, and account for relaxivities

E. Lee¹, J. Park¹, W. Xu¹, K. Kattel¹, H. Kim¹, and G. Lee¹

¹Department of Chemistry, Kyungpook National University, Daegu, Gyeongsangbuk-do, Korea, Republic of

Introduction

We report the synthesis of water-soluble MnO nanocolloid with a monodisperse core particle diameter (d) ranging from 2 to 3 nm. The magnetic nanocolloids with d in this size range will be very useful as T_1 MRI contrast agents because first of all, they can be easily excreted through kidneys because of their small sizes, which is an essential requirement for clinical application, and because they can have high r_1 relaxivities due to their high surface to volume ratio (P), as observed in the Gd_2O_3 nanocolloid. This is because only the surface metal ions in a nanoparticle are mainly active for the longitudinal water proton relaxation. In the case of the Gd_2O_3 nanocolloid, the optimal d for the maximal r_1 relaxivity was found to be between 1.0 and 2.5 nm. This is opposite to a T_2 MRI contrast agent, which has a somewhat large d . This is because the magnetic moment (M) which induces the r_2 relaxivity rapidly decreases with decreasing the d . For this reason, the T_2 MRI contrast agent such as the superparamagnetic iron oxide (SPIO) nanocolloid at least has a d value greater than 5 nm and thus is used only as a liver-specific T_2 MRI contrast agent.

Material and Methods

10 mmol of $MnCl_2 \cdot 4H_2O$ and 30 mL of triethylene glycol were added to a 100 mL three-necked flask and the mixture was magnetically stirred at room temperature under N_2 gas flow. Separately, 20 mmol of NaOH was dissolved in 10 mL of solvent. The latter solution was slowly added to the former solution through a syringe after the precursor was completely dissolved in the solvent. The reaction temperature was raised to 200 °C and kept at that temperature for 6 hours. The reaction temperature was lowered to 140 °C and then, 10 mmol of D-glucuronic acid was added to the reaction solution. The reaction continued for more 24 hours. The reaction solution was cooled to room temperature and then, transferred to a 1 L beaker. The solvent, unreacted coating ligand, unreacted Mn(II), and Cl^- ions were removed from the reaction solution by washing it with distilled water three times. To do this, we added 500 mL of distilled water to the reaction solution, and then magnetically stirred it for ~30 min. The reaction solution was kept for a week or so until the MnO nanocolloid was settled down to the bottom of the solution. The top transparent solution was decanted. This procedure was repeated three times. Half of the MnO nanocolloid was dispersed in distilled water to prepare a MRI solution. The remaining half was dried in air to prepare a powder sample for characterizations.

Results and Discussion

From DLS particle size analyzer, the average diameter of the MnO nanocolloid was estimated to be 5 nm. The data from SQUID magnetometer suggest that the MnO nanoparticle was nearly paramagnetic down to 3 K and showed a high magnetic moment of ~90 emu/g at $T = 5$ K and $H = 5$ T, which mainly arises from surface Mn(II) ions with $S = 5/2$ as well as a decent P (≈ 0.35) of the MnO nanoparticle. For these reasons, a high r_1 relaxivity of $7.02 \text{ s}^{-1} \text{ mM}^{-1}$ was observed. This value is higher than those of the clinically used metal ion chelated MRI contrast agents. The observed r_2 relaxivity of $47.97 \text{ s}^{-1} \text{ mM}^{-1}$ is likely due to a tiny M of the MnO nanoparticle arising from incomplete spin cancellation of antiferromagnetic spins of its inside Mn(II) ions. *In vivo* testing of an MRI solution showed high contrast T_1 MR images, proving that the MnO nanocolloid functions as a sensitive T_1 MRI contrast agent.

Conclusion

High contrast *in vivo* T_1 MR images were obtained for various organs, showing the capability of the MnO nanocolloid as a sensitive T_1 MRI contrast agent. The suggested three key-parameters which control the r_1 and r_2 relaxivities of nanocolloids (i.e., the S value of a metal ion, the spin structure, and the surface to volume ratio of a nanoparticle) successfully accounted for the observed r_1 and r_2 relaxivities of the MnO nanocolloid.

Figure 1.
(a-c) HRTEM images of the MnO nanocolloid at different magnifications.




Figure 2.
A series of 1.5 T *in vivo* T_1 MR images of a mouse with time after injection of a MRI solution into a mouse tail vein.




Figure 3.
MR signal intensity variations with time in both liver and kidneys after injection of a MRI solution into a mouse tail vein.




Figure 4.
(a) R_1 and (b) R_2 map images of MRI solutions as function of Mn concentration.

